Familial dysalbuminemic hyperthyroxinemia combined with Graves' disease: a rare case report.

Case report Familial dysalbuminemic hyperthyroxinemia Graves’ disease Hypothyroidism Syndromes of inappropriate secretion of thyroid stimulating hormone

Journal

BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676

Informations de publication

Date de publication:
18 Oct 2023
Historique:
received: 10 02 2023
accepted: 08 10 2023
medline: 23 10 2023
pubmed: 19 10 2023
entrez: 18 10 2023
Statut: epublish

Résumé

Familial dysalbuminemic hyperthyroxinemia (FDH) is an autosomal dominant disease characterised by an abnormally increased affinity of albumin for serum thyroxine. Assay interference and differential diagnosis remain challenging for FDH. The condition is more complicated when FDH is combined with primary thyroid diseases. Co-occurrence of FDH and Graves' disease is rare. We report the case of a 28-year-old woman with complex FDH and coexisting Graves' disease. Initially, the existence of FDH was not recognised. Graves' disease was relieved after treatment with antithyroid drugs and two administrations of radioactive iodine therapy. She subsequently developed primary hypothyroidism and was prescribed levothyroxine replacement. However, thyroid function failed to normalise despite frequent levothyroxine dose adjustments. Ultimately, syndromes involving the inappropriate secretion of thyroid-stimulating hormone (IST) were considered, and FDH was successfully differentiated from other causes of IST. A greater focus on FDH when investigating the causes of IST is critical to correctly evaluate thyroid function status and avoid inappropriate treatment, especially in complicated cases with concurrent FDH and primary thyroid diseases.

Sections du résumé

BACKGROUND BACKGROUND
Familial dysalbuminemic hyperthyroxinemia (FDH) is an autosomal dominant disease characterised by an abnormally increased affinity of albumin for serum thyroxine. Assay interference and differential diagnosis remain challenging for FDH. The condition is more complicated when FDH is combined with primary thyroid diseases. Co-occurrence of FDH and Graves' disease is rare.
CASE PRESENTATION METHODS
We report the case of a 28-year-old woman with complex FDH and coexisting Graves' disease. Initially, the existence of FDH was not recognised. Graves' disease was relieved after treatment with antithyroid drugs and two administrations of radioactive iodine therapy. She subsequently developed primary hypothyroidism and was prescribed levothyroxine replacement. However, thyroid function failed to normalise despite frequent levothyroxine dose adjustments. Ultimately, syndromes involving the inappropriate secretion of thyroid-stimulating hormone (IST) were considered, and FDH was successfully differentiated from other causes of IST.
CONCLUSIONS CONCLUSIONS
A greater focus on FDH when investigating the causes of IST is critical to correctly evaluate thyroid function status and avoid inappropriate treatment, especially in complicated cases with concurrent FDH and primary thyroid diseases.

Identifiants

pubmed: 37853391
doi: 10.1186/s12902-023-01481-5
pii: 10.1186/s12902-023-01481-5
pmc: PMC10583390
doi:

Substances chimiques

Thyroxine Q51BO43MG4
Serum Albumin 0
Iodine Radioisotopes 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

226

Subventions

Organisme : Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science
ID : 2021-1-I2M-022
Organisme : Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science
ID : 2021-1-I2M-022

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

Endocrinol Diabetes Metab Case Rep. 2020 Feb 26;2020:
pubmed: 32101523
Front Endocrinol (Lausanne). 2017 Nov 01;8:297
pubmed: 29163366
Eur J Endocrinol. 1995 Dec;133(6):729-31
pubmed: 8548059
Endocrine. 2016 Jun;52(3):427-40
pubmed: 26792794
Clin Chem. 2009 May;55(5):1044-6
pubmed: 19282355
Eur Thyroid J. 2013 Jun;2(2):76-82
pubmed: 24783044
Am J Med. 1987 Feb;82(2):221-3
pubmed: 3812513
Eur J Endocrinol. 2020 Jun;182(6):533-538
pubmed: 32213658
Thyroid. 2020 Sep;30(9):1236-1244
pubmed: 32212919
Biochim Biophys Acta. 2013 Jul;1830(7):3987-4003
pubmed: 22986150
Br Med J (Clin Res Ed). 1987 Jan 31;294(6567):286
pubmed: 3101845
Am J Med Sci. 2020 Nov;360(5):566-574
pubmed: 32665066
J Clin Med. 2020 Jul 03;9(7):
pubmed: 32635414
Lancet. 1979 Mar 24;1(8117):639-42
pubmed: 85873
J Clin Endocrinol Metab. 1979 Aug;49(2):292-9
pubmed: 110823

Auteurs

Yuanmeng Li (Y)

Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Yue Chi (Y)

Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Xiaofeng Chai (X)

Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

He Liu (H)

Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Naishi Li (N)

Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. LNS@medmail.com.cn.
State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. LNS@medmail.com.cn.
Department of Medical Records, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. LNS@medmail.com.cn.
WHO Family of International Classifications Collaborating Center of China, Beijing, China. LNS@medmail.com.cn.

Xiaolan Lian (X)

Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. lianlanx@126.com.
State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. lianlanx@126.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH